Stockreport

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Valneva SE - American Depositary Shares  (VALN) 
PDF Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age gr [Read more]